Clinical Trial Update: Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents [Phase 3]

View source ↗

Summary

Phase 3 trial investigating safety and immunogenicity of catch-up vaccination with PCV21 in healthy infants to adolescents.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• PCV21 (Pneumococcal conjugate vaccine, 21-valent)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Pneumococcal Infections | Phase 3 | Status: ACTIVE_NOT_RECRUITING